Soru

Zorluk: KolayPreventive Care and Screening

A 23-year-old female college student presents to the university health clinic for a routine wellness examination. She reports feeling well and has no specific complaints. Her medical history is unremarkable, and she currently takes an oral contraceptive pill daily. She mentions that she recently became sexually active with a new male partner. Review of her immunization records confirms she completed the human papillomavirus (HPV) vaccine series at age 12. According to current United States Preventive Services Task Force (USPSTF) guidelines, which of the following screening interventions are indicated for this patient during today's visit? (Select all that apply)

  1. Cervical cytology aloneCevap
  2. Nucleic acid amplification testing for Chlamydia trachomatis and Neisseria gonorrhoeaeCevap
  3. C
    High-risk human papillomavirus (hrHPV) testing
  4. D
    Serologic testing for herpes simplex virus type 2
  5. E
    Routine transvaginal ultrasonography for ovarian cancer screening

Cevap

The indicated interventions are cervical cytology alone and nucleic acid amplification testing for Chlamydia trachomatis and Neisseria gonorrhoeae.
The patient is a sexually active 23-year-old female. According to USPSTF guidelines, sexually active women under the age of 25 should be screened annually for Chlamydia trachomatis and Neisseria gonorrhoeae (Grade B recommendation). Additionally, routine cervical cancer screening begins at age 21, and for women aged 21 to 29, the recommendation is screening every 3 years with cervical cytology alone (Grade A recommendation). Both of these interventions directly apply to this patient's presentation.

Adım Adım Çözüm

1
Analyze the patient's demographic and social history.
The patient is a 23-year-old sexually active female with a new partner.
Age and sexual activity status dictate specific USPSTF preventive screening recommendations in young adult females.
2
Determine appropriate cervical cancer screening for her age group.
Cervical cytology alone is indicated.
For women aged 21 to 29, the USPSTF recommends screening every 3 years with cytology alone. Co-testing or primary HPV testing is reserved for women aged 30 and older.
3
Determine appropriate sexually transmitted infection (STI) screening.
Chlamydia and gonorrhea screening is indicated.
The USPSTF recommends screening for chlamydia and gonorrhea in all sexually active women 24 years or younger, as well as in older women who are at increased risk.

Anahtar Kavram

Preventive screening guidelines for sexually active young adult females
Bu soruyu puanla